Imaging software developer Median Technologies is reporting double-digit percentage revenue gains for 2022.
For the year (end-December 31), Median had revenues of 23.8 million euros, up 16% compared with the 16.5 million euros produced in 2021. As of December 31, Median had a backlog of 60.8 million euros.
The company's revenue is generated "entirely" by the iCRO division's commercial activity, Median said in its financial report. Among the company's highlights from the past year include launching Imaging Lab to extract imaging data from cancer trials and initiating discussions with the U.S. Food and Drug Administration around obtaining clearance for its iBiopsy lung cancer screening software.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
